Targeting hypoxia in cancer therapy

Nature Reviews Cancer

Volumn 11, Issue 6, 2011, Pages 393-410

  Wilson, William R ^a   Hay, Michael P ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE; 5 BROMOISOQUINOLONE; ACETYLSALICYLIC ACID; AKR 1C3; ANTINEOPLASTIC AGENT; APAZIQUONE; BANOXANTRONE; BETA AMINOPROPRIONITRILE; BLEOMYCIN; CARICOTAMIDE; CHLORAMBUCIL; CISPLATIN; COMBRETASTATIN A4; DINITROBENZAMIDE; DOXORUBICIN; ETOPOSIDE; EZN 2968; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN C; PIMONIDAZOLE; PR 104; SN 29730; SN 29966; SN 30000; TAXANE DERIVATIVE; TIRAPAZAMINE; TRETAZICAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; BREAST CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE ARREST; CELL DEATH; CELL KILLING; CELL SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA DAMAGE; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENOMIC INSTABILITY; HEAD AND NECK CARCINOMA; HOMOLOGOUS RECOMBINATION; HUMAN; HYPOXIA; HYPOXIC CELL; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; OVERALL SURVIVAL; OXYGEN CONCENTRATION; PANCREAS CANCER; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; TUMOR GROWTH; UTERINE CERVIX CARCINOMA; XENOBIOTIC METABOLISM;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRODRUGS; PROGNOSIS; REACTIVE OXYGEN SPECIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79957534572     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3064     Document Type: Review

References (187)

1. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
2. Pries, A. R. et al. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput. Biol. 5, e1000394 (2009).
3. Dewhirst, M. W., Cao, Y. & Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Rev. Cancer 8, 425-437 (2008). (Pubitemid 351744964)
4. Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996). (Pubitemid 26008141)
5. Erler, J. T. et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell. Biol. 24, 2875-2889 (2004). (Pubitemid 38381277)
6. Rouschop, K. M. et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG 5 . J. Clin. Invest. 120, 127-141 (2010).
7. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nature Rev. Cancer 11, 85-95 (2011).
8. Wang, Y. & Ohh, M. Oxygen-mediated endocytosis in cancer. J. Cell. Mol. Med. 14, 496-503 (2010).
9. Semenza, G. L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35, 71-103 (2000). (Pubitemid 30253678)
10. Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694-705 (2010).
11. Hill, R. P., Marie-Egyptienne, D. T. & Hedley, D. W. Cancer stem cells, hypoxia and metastasis. Semin. Radiat. Oncol. 19, 106-111 (2009).
12. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 3, 347-361 (2003). (Pubitemid 38340304)
13. Chang, Q., Jurisica, I., Do, T. & Hedley, D. W. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res. 78, 3110-3120 (2011).
14. Yotnda, P., Wu, D. & Swanson, A. M. Hypoxic tumours and their effect on immune cells and cancer therapy. Methods Mol. Biol. 651, 1-29 (2010).
15. Guzy, R. D. et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell. Metab. 1, 401-408 (2005). (Pubitemid 43960623)
16. Bristow, R. G. & Hill, R. P. Hypoxia, DNA repair and genetic instability. Nature Rev. Cancer 8, 180-192 (2008).
17. Vaupel, P., Hockel, M. & Mayer, A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signal. 9, 1221-1235 (2007). (Pubitemid 47080831)
18. Tatum, J. L. et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82, 699-757 (2006). (Pubitemid 44832019)
19. Jubb, A. M., Buffa, F. M. & Harris, A. L. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J. Cell. Mol. Med. 14, 18-29 (2010).
20. Connors, T. A. & Whisson, M. E. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 210, 866-867 (1966).
21. 2 inhibition of nitroreductase. Biochem. Biophys. Res. Commun. 67, 1267-1274 (1975).
22. Mohindra, J. K. & Rauth, A. M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 36, 930-936 (1976).
23. Adams, G. E., Dische, S., Fowler, J. F. & Thomlinson, R. H. Hypoxic cell sensitisers in radiotherapy. Lancet 1, 186-188 (1976).
24. Wardman, P. Chemical radiosensitizers for use in radiotherapy. Clin. Oncol. 19, 397-417 (2007). (Pubitemid 46995615)
25. Schwartz, H. S., Sodergren, J. E. & Philips, F. S. Mitomycin C: chemical and biological studies on alkylation. Science 142, 1181-1183 (1963).
26. Iyer, V. N. & Szybalski, W. Mitomycins and porfiromycins: chemical mechanism of activation and cross-linking of DNA. Science 145, 55-58 (1964).
27. Lin, A. J., Cosby, L. A., Shanky, C. W. & Sartorelli, A. C. Potential bioreductive alkylating agents. I. Benzoquinone derivatives. J. Med. Chem. 15, 1247-1252 (1972).
28. Carter, D. B. & Phillips, A. F. Measurement of electrode potentials in living and dead tissues. Nature 174, 121-123 (1954).
29. Kennedy, K. A., Rockwell, S. & Sartorelli, A. C. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res. 40, 2356-2360 (1980). (Pubitemid 10082250)
30. Bachur, N. R., Gordon, S. L. & Gee, M. V. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res. 38, 1745-1750 (1978). (Pubitemid 8349723)
31. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67, 1163-1170 (1993). (Pubitemid 23172847)
32. 2. J. Am. Chem. Soc. 129, 12870-12877 (2007). (Pubitemid 350004499)
33. Shinde, S. S., Hay, M. P., Patterson, A. V., Denny, W. A. & Anderson, R. F. Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J. Am. Chem. Soc. 131, 14220-14221 (2009).
34. Patterson, L. H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 12, 119-134 (1993). (Pubitemid 23220676)
35. Wilson, W. R., van Zijl, P. & Denny, W. A. Bisbioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. Int. J. Radiat. Oncol. Biol. Phys. 22, 693-696 (1992).
36. Ware, D. C., Palmer, B. D., Wilson, W. R. & Denny, W. A. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J. Med. Chem. 36, 1839-1846 (1993). (Pubitemid 23203741)
37. Ahn, G. O. et al. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem. Pharmacol. 71, 1683-1694 (2006).
38. Parker, L. L. et al. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J. Med. Chem. 47, 5683-5689 (2004). (Pubitemid 39447265)
39. Weiss, G. J. et al. Phase 1 study of the safety, tolerability and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin. Cancer Res. 17, 2997-3004 (2011).
40. Wardman, P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem. 8, 739-761 (2001). (Pubitemid 32427904)
41. Stratford, I. J., Williams, K. J., Cowen, R. L. & Jaffar, M. Combining bioreductive drugs and radiation for the treatment of solid tumors. Semin. Radiat. Oncol. 13, 42-52 (2003). (Pubitemid 36173259)
42. Ahn, G. O. & Brown, M. Targeting tumors with hypoxia-activated cytotoxins. Front. Biosci. 12, 3483-3501 (2007).
43. Chen, Y. & Hu, L. Design of anticancer prodrugs for reductive activation. Med. Res. Rev. 29, 29-64 (2009).
44. Tercel, M. et al. Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins. Angew. Chem. Int. Ed. 50, 2606-2609 (2011).
45. Evans, J. W. et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res. 68, 257-265 (2008). (Pubitemid 351380127)
46. Gu, Y. et al. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol. Cancer Ther. 8, 1714-1723 (2009).
47. Branzei, D. & Foiani, M. Maintaining genome stability at the replication fork. Nature Rev. Mol. Cell Biol. 11, 208-219 (2010).
48. Raleigh, S. M., Wanogho, E., Burke, M. D., McKeown, S. R. & Patterson, L. H. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int. J. Radiat. Oncol. Biol. Phys. 42, 763-767 (1998). (Pubitemid 28559413)
49. Nishida, C. R., Lee, M. & Ortiz de Montellano, P. R. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol. Pharmacol. 78, 497-502 (2010).
50. Rivera, S. P. et al. A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia. J. Biol. Chem. 282, 10881-10893 (2007). (Pubitemid 47100738)
51. Nishida, C. R. & Ortiz de Montellano, P. R. Reductive heme-dependent activation of the N-oxide prodrug AQ4N by nitric oxide synthase. J. Med. Chem. 51, 5118-5120 (2008).
52. Colucci, M. A., Moody, C. J. & Couch, G. D. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Org. Biomol. Chem. 6, 637-656 (2008).
53. Knox, R. J. et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitro-benzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxyla- mino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 37, 4671-4677 (1988). (Pubitemid 19006306)
54. Celli, C. M., Tran, N., Knox, R. & Jaiswal, A. K. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem. Pharmacol. 72, 366-376 (2006). (Pubitemid 43975085)
55. Yan, C., Kepa, J. K., Siegel, D., Stratford, I. J. & Ross, D. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2, 5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzo quinone (RH1). Mol. Pharmacol. 74, 1657-1665 (2008).
56. Guise, C. P. et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 70, 1573-1584 (2010).
57. Adikesavan, A. K., Barrios, R. & Jaiswal, A. K. In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity. Cancer Res. 67, 7966-7971 (2007). (Pubitemid 47395126)
58. Siegel, D. & Ross, D. Immunodetection of NAD(P) H:quinone oxidoreductase 1 (NQO1) in human tissues 6. Free Rad. Biol. Med. 29, 246-253 (2000).
59. Wang, W. & Jaiswal, A. K. Nuclear factor Nrf2 and antioxidant response element regulate NRH:quinone oxidoreductase 2 (NQO2) gene expression and antioxidant induction. Free Rad. Biol. Med. 40, 1119-1130 (2006).
60. MacLeod, A. K. et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 30, 1571-1580 (2009).
61. Cullinan, S. B. & Diehl, J. A. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int. J. Biochem. Cell. Biol. 38, 317-332 (2006). (Pubitemid 41821881)
62. Jain, A. et al. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 73, 1083-1086 (2009).
63. Danson, S. J. et al. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Ann. Oncol. 4 Mar 2011 (doi:10.1093/annonc/ mdq638).
64. Birtwistle, J. et al. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a) anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat. Res. 662, 67-74 (2009).
65. Konopleva, M. et al. Therapeutic targeting of the hypoxic microenvironment in acute lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 11 4, Abstract 2040 [online], http://ash.confex.com/ ash/2009/webprogram/Paper24327.html (2009).
66. Hu, J. et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 116, 1524-1527 (2010).
67. Baker M. A., Zeman, E. M., Hirst, V. K. & Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 48 5947-5952 1988). (Pubitemid 18266781)
68. Hicks, K. O. et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 16, 4946-4957 (2010).
69. Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nature Rev. Cancer 6, 583-592 (2006). (Pubitemid 44140857)
70. Durand, R. E. & Olive, P. L. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat. Oncol. Investig. 5, 213-219 (1997). (Pubitemid 27479449)
71. Durand, R. E. & Olive, P. L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys. 22, 689-692 (1992).
72. Hicks, K. O., Fleming, Y., Siim, B. G., Koch, C. J. & Wilson, W. R. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 42, 641-649 (1998). (Pubitemid 28501116)
73. Kyle, A. H. & Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 43, 213-220 (1999). (Pubitemid 29042489)
74. Hicks, K. O. et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl Cancer Inst. 98, 1118-1128 (2006). (Pubitemid 44288786)
75. Pruijn, F. B., Patel, K., Hay, M. P., Wilson, W. R. & Hicks, K. O. Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters. Aust. J. Chem. 61, 687-693 (2008).
76. Hay, M. P. et al. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. J. Med. Chem. 50, 6654-6664 (2007). (Pubitemid 350309102)
77. Koch, C. J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 53, 3992-3997 (1993). (Pubitemid 23267700)
78. Hicks, K. O., Siim, B. G., Pruijn, F. B. & Wilson, W. R. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat. Res. 161, 656-666 (2004). (Pubitemid 39149574)
79. Marshall, R. S. & Rauth, A. M. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res. 48, 5655-5659 (1988).
80. Siim, B. G., Atwell, G. J. & Wilson, W. R. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br. J. Cancer 70, 596-603 (1994). (Pubitemid 24305583)
81. Wilson, W. R., Moselen, J. W., Cliffe, S., Denny, W. A. & Ware, D. C. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771. Int. J. Radiat. Oncol. Biol. Phys. 29, 323-327 (1994). (Pubitemid 24166540)
82. Wilson, W. R. et al. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat. Res. 167, 625-636 (2007). (Pubitemid 351292942)
83. Hicks, K. O. et al. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int. J. Radiat. Oncol. Biol. Phys. 69, 560-571 (2007). (Pubitemid 47380109)
84. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nature Rev. Cancer 8, 193-204 (2008). (Pubitemid 351301852)
85. Parveen, I., Naughton, D. P., Whish, W. J. & Threadgill, M. D. 2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5- bromoisoquinolinone. Bioorg. Med. Chem. Lett. 9, 2031-2036 (1999). (Pubitemid 29336395)
86. Everett, S. A., Naylor, M. A., Patel, K. B., Stratford, M. R. L. & Wardman, P. Bioreductively-activated prodrugs for targetting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives. Bioorg. Med. Chem. Lett. 9, 1267-1272 (1999). (Pubitemid 29207445)
87. Thomson, P. et al. Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4. Mol. Cancer Ther. 5, 2886-2894 (2006). (Pubitemid 44849016)
88. Granchi, C. et al. Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours. ChemMedChem 4, 1590-1594 (2009).
89. Tercel, M., Wilson, W. R., Anderson, R. F. & Denny, W. A. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J. Med. Chem. 39, 1084-1094 (1996). (Pubitemid 26082941)
90. Patterson, A. V. et al. Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia-activated irreversible pan-HER inhibitor. Mol. Cancer Ther. 8 (Suppl. 1), B76 (2009).
91. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003). (Pubitemid 37328811)
92. Poon, E., Harris, A. L. & Ashcroft, M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev. Mol. Med. 11, e26 (2009).
93. Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature Rev. Cancer. 8, 851-864 (2008).
94. Martinive, P. et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for cancer therapies. Cancer Res. 66, 11736-11744 (2006). (Pubitemid 46094185)
95. Semenza, G. L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 12, 853-859 (2007). (Pubitemid 47554628)
96. Giaccia, A., Siim, B. G. & Johnson, R. S. HIF-1 as a target for drug development. Nature Rev. Drug Discov. 2, 803-811 (2003). (Pubitemid 37361812)
97. Melillo, G. Targeting hypoxia cell signalling for cancer therapy. Cancer Metastasis Rev. 26, 341-352 (2007). (Pubitemid 47101663)
98. Isaacs, J. S. et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277, 29936-29944 (2002).
99. Kizaka-Kondoh, S., Tanaka, S., Harada, H. & Hiraoka, M. The HIF-1-active microenvironment: an environmental target for cancer therapy. Advanced Drug Deliv. Rev. 61, 623-632 (2009).
100. Rouschop, K. M. & Wouters, B. G. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr. Mol. Med. 9, 417-424 (2009).
101. 2-dependent reaction cycle of Ero1-mediated oxidative protein folding in the endoplasmic reticulum. Mol. Cell 10, 983-994 (2002). (Pubitemid 35453820)
102. Koditz, J. et al. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110, 3610-3617 (2007). (Pubitemid 350159628)
103. Bi, M. et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 24, 3470-3481 (2005). (Pubitemid 41486784)
104. Romero-Ramirez, L. et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64, 5943-5947 (2004). (Pubitemid 39129389)
105. Spiotto, M. T. et al. Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res. 70, 78-88 (2010).
106. Papandreou, I. et al. Identification of an Ire1á endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 11 7, 1311-1314 (2011).
107. Volkmann, K. et al. Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J. Biol. Chem. 286, 12743-12755 (2011).
108. Lee, K. P. et al. Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. Cell 132, 89-100 (2008).
109. Fels, D. R. et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res. 68, 9323-9330 (2008).
110. Koumenis, C. & Wouters, B. G. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol. Cancer Res. 4, 423-436 (2006). (Pubitemid 44197038)
111. Brugarolas, J. et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893-2904 (2004). (Pubitemid 39602308)
112. Liu, L. et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21, 521-531 (2006). (Pubitemid 43228007)
113. Li, Y. et al. BNIP3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J. Biol. Chem. 282, 35803-35813 (2007). (Pubitemid 350277153)
114. Pencreach, E. et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/ hypoxia-inducible factor-1á axis. Clin. Cancer Res. 15, 1297-1307 (2009).
115. Yu, K. et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res. 70, 621-631 (2010).
116. Rzymski, T. et al. Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 29, 4424-4435 (2010).
117. Marin-Hernandez, A., Gallardo-Perez, J. C., Ralph, S. J., Rodriguez-Enriquez, S. & Moreno-Sanchez, R. HIF-1á modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini-Rev. Med. Chem. 9, 1084-1101 (2009).
118. Levine, A. J. & Puzio-Kuter, A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344 (2010).
119. Kurtoglu, M., Maher, J. C. & Lampidis, T. J. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antiox. Redox Signal. 9, 1383-1390 (2007). (Pubitemid 47255017)
120. Song, C. W., Clement, J. J. & Levitt, S. H. Preferential cytotoxicity of 5-thio-D-glucose against hypoxic tumor cells. J. Natl Cancer Inst. 57, 603-605 (1976).
121. Lampidis, T. J. et al. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother. Pharmacol. 58, 725-734 (2006). (Pubitemid 44351251)
122. Macheda, M. L., Rogers, S. & Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202, 654-662 (2005). (Pubitemid 40175840)
123. Wood, T. E. et al. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol. Cancer Ther. 7, 3546-3555 (2008).
124. Lai, E. W., Chan, D. A., Hay, M. P. & Giaccia, A. J. Selective cytotoxic targeting of von Hippel-Lindau-deficient renal carcinoma cells. Proc. Am. Assoc. Cancer Res. 51, Abstract 67 (2010).
125. Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942 (2008).
126. Ovens, M. J., Davies, A. J., Wilson, M. C., Murray, C. M. & Halestrap, A. P. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem. J. 425, 523-530 (2010).
127. Murray, C. M. et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nature Chem. Biol. 1, 371-376 (2005).
128. Chiche, J., Brahimi-Horn, M. C. & Pouyssegur, J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell. Mol. Med. 14, 771-794 (2010).
129. Ullah, M. S., Davies, A. J. & Halestrap, A. P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1á-dependent mechanism. J. Biol. Chem. 281, 9030-9037 (2006). (Pubitemid 43864615)
130. Gallagher, S. M., Castorino, J. J., Wang, D. & Philp, N. J. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 67, 4182-4189 (2007). (Pubitemid 46815064)
131. Chiche, J. et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 69, 358-368 (2009).
132. Van den Beucken, T. et al. Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J. Biol. Chem. 284, 24204-24212 (2009).
133. Lou, Y. et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 71, 3364-3376 (2011).
134. Huang, L. E., Bindra, R. S., Glazer, P. M. & Harris, A. L. Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J. Mol. Med. 85, 139-148 (2007). (Pubitemid 46188219)
135. Olcina, M., Lecane, P. S. & Hammond, E. M. Targeting hypoxic cells through the DNA damage response. Clin. Cancer Res. 16, 5620-5629 (2010).
136. Chan, N., Koch, C. J. & Bristow, R. G. Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr. Mol. Med. 9, 401-410 (2009).
137. Hammond, E. M., Green, S. L. & Giaccia, A. J. Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat. Res. 532, 205-213 (2003). (Pubitemid 37487854)
138. Pires, I. M. et al. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res. 70, 925-935 (2010).
139. Norlund, P. & Reichard, P. Ribonucleotide reductases. Ann. Rev. Biochem. 75, 681-706 (2006). (Pubitemid 44118048)
140. Hammond, E. M., Dorie, M. J. & Giaccia, A. J. Inhibition of AT R leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res. 64, 6556-6562 (2004). (Pubitemid 39297914)
141. Hammond, E. M., Dorie, M. J. & Giaccia, A. J. ATR/ ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 278, 12207-12213 (2003). (Pubitemid 36800201)
142. Gibson, S. L., Bindra, R. S. & Glazer, P. M. CHK2-dependent phosphorylation of BRCA1 in hypoxia. Radiat. Res. 166, 646-651 (2006). (Pubitemid 44477718)
143. Chang, C.-J. et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-â-catenin signaling. Cancer Cell 19, 86-100 (2011).
144. Marotta, D. et al. In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Res. 71, 779-789 (2011).
145. Bindra, R. S. et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell. Biol. 24, 8504-8518 (2004). (Pubitemid 39245072)
146. Chan, N. et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 68, 605-614 (2008). (Pubitemid 351380090)
147. Chan, N. et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 70, 8045-8054 (2010).
148. Di Cintio, A., Di Gennaro, E. & Budillon, A. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis. Recent Pat. Anti-Cancer Drug Discov. 5, 1-13 (2010).
149. Yang, J. et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1á and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol. Cell. Biol. 29, 2243-2253 (2009).
150. Hoogsteen, I. J. et al. Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia. Eur. J. Cancer 45, 2906-2914 (2009).
151. Nordsmark, M. et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 77, 18-24 (2005). (Pubitemid 41503384)
152. Mees, G., Dierckx, R., Vangestel, C. & Van De, W. C. Molecular imaging of hypoxia with radiolabelled agents. Eur. J. Nucl. Med. Mol. Imag. 36, 1674-1686 (2009).
153. Mason, R. P. et al. Multimodality imaging of hypoxia in preclinical settings. Quart. J. Nucl. Med. Mol. Imag. 54, 259-280 (2010).
154. Workman, P. & Stratford, I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 12, 73-82 (1993). (Pubitemid 23220673)
155. Willers, H. et al. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol. Cancer Res. 7, 1304-1309 (2009).
156. Konstantinopoulos, P. A. et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28, 3555-3561 (2010).
157. Graeser, M. et al. A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159-6158 (2010).
158. Wang, J. et al. EF5 as a predictive biomarker for activation of the new hypoxia targeting prodrug SN30000. Am. Soc. Clin. Oncol. Abstract e13597, (2011).
159. Hedley, D. et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin. Cancer Res. 9, 5666-5674 (2003). (Pubitemid 37499489)
160. Whitehurst, A. W. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007). (Pubitemid 46582032)
161. Barabasi, A.-L., Gulbache, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nature Rev. Genet. 12, 56-68 (2011).
162. Moeller, B. J., Cao, Y., Li, C. Y. & Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-441 (2004). (Pubitemid 38610245)
163. Garner, A. P. et al. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 59, 1929-1934 (1999). (Pubitemid 29186167)
164. Chinje, E. C. et al. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol. Pharmacol. 63, 1248-1255 (2003). (Pubitemid 36627219)
165. Thomsen, L. L. et al. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 72, 41-44 (1995).
166. Swana, H. S. et al. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol. 161, 630-634 (1999).
167. Lewis, C. & Murdoch, C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol. 167, 627-635 (2005). (Pubitemid 41216349)
168. Melillo, G. et al. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182, 1683-1693 (1995).
169. Tendler, D. S. et al. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res. 61, 3682-3688 (2001). (Pubitemid 32694980)
170. Chinje, E. C. et al. 17â-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response. Br. J. Cancer 86, 136-142 (2002). (Pubitemid 34146354)
171. Patterson, L. H. & McKeown, S. R. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br. J. Cancer 83, 1589-1593 (2000). (Pubitemid 32001698)
172. Chandor, A. et al. Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. Chem. Res. Toxicol. 21, 836-843 (2008). (Pubitemid 351644561)
173. Guise, C. P. et al. Identification of human oxidoreductases involved in the hypoxia-dependent activation of bioreductive prodrugs. Proc. Am. Assoc. Cancer Res. 51, Abstract 453 (2010).
174. Kan, O. et al. Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer. Int. J. Mol. Med. 27, 173-180 (2011).
175. Cowen, R. L. et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res. 64, 1396-1402 (2004). (Pubitemid 38235608)
176. 5 reductase. Cancer Res. 53, 4907-4912 (1993). (Pubitemid 23326186)
177. Miskiniene, V., Dickancaite, E., Nemeikaite, A. & Cenas, N. Nitroaromatic betulin derivatives as redox cycling agents. Biochem. Mol. Biol. Int. 42, 391-397 (1997). (Pubitemid 28297687)
178. Kutcher, W. W. & McCalla, D. R. Aerobic reduction of 5-nitro-2-furaldehyde semicarbazone by rat liver xanthine dehydrogenase. Biochem. Pharmacol. 33, 799-805 (1984). (Pubitemid 14166451)
179. Ahlskog, J. K. et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br. J. Cancer 101, 645-657 (2009).
180. Hoeben, B. A. et al. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J. Nucl. Med. 51, 1076-1083 (2010).
181. Kaluz, S., Kaluzova, M., Liao, S. Y., Lerman, M. & Stanbridge, E. J. Transcriptional control of the tumor-and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim. Biophys. Acta 1795, 162-172 (2009).
182. Komar, G. et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J. Nucl. Med. 49, 1944-1951 (2008).
183. Rischin, D. et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J. Clin. Oncol. 24, 2098-2104 (2006). (Pubitemid 46622121)
184. Rischin, D. et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 28, 2989-2995 (2010).
185. Wouters, B. G. & Brown, J. M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 147, 541-550 (1997). (Pubitemid 27204090)
186. Tuttle, S. W. et al. Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration. J. Biol. Chem. 282, 36790-36796 (2007).
187. Rzymski, T. & Harris, A. L. The unfolded protein response and integrated stress response to anoxia. Clin. Cancer Res. 13, 2537-2540 (2007). (Pubitemid 46788018)